The partnership between MedShift and Merz North America is powered by both companies’ equal and respective appreciation for cutting-edge product development innovation for physicians and the drive to improve health and quality of life for patients, according to a media release from MedShift.
“Following the successful rebrand of vConfidence, MedShift is excited to expand our portfolio with this partnership to offer more valuable and innovative solutions for today’s woman,” says MedShift’s CEO, Brian Phillips.
This partnership will bring more awareness to Cellfina, a state-of-the-art, FDA-cleared device that provides long-lasting reversal of cellulite. The device shows 5 years of sustained results with no recurring symptoms. As part of the partnership, MedShift will launch Effronté as a means by which to make the Cellfina technology more accessible to more women, the release continues.
“This partnership is going to do great things for both Merz North America and MedShift,” states MedShift Medical Director Dr Bill Kortesis, FACS, and board-certified plastic surgeon. “We’re looking forward to seeing what’s possible when we combine the Cellfina device with MedShift’s technology.”
This partnership is part of a continued investment by MedShift in women’s health. Since 2015, MedShift has invested over $10,000,000 in procedures to improve and enhance women’s lives.
“Our goal with this partnership and the Effronté brand is to make women feel more confident,” Phillips adds. “Because, when a woman feels like that, she’s unstoppable.”
[Source(s): MedShift, PR Newswire]